Study Looks at Survival in Metastatic NSCLC Treated With Immunotherapy
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 13, 2023 -- For patients with metastatic non-small cell lung cancer (NSCLC) receiving immunotherapy, outcomes are similar across racial and ethnic groups, but ECOG performance status (PS) is associated with survival, according to a study published online Dec. 11 in the Journal of the National Comprehensive Cancer Network.
Matthew Lee, M.D., M.P.H., from the Albert Einstein College of Medicine in Bronx, New York, and colleagues conducted a retrospective cohort study of 5,920 patients diagnosed with lung cancer treated from Jan. 1, 2013, to June 1, 2022. A total of 248 patients (39.1, 30.2, and 30.7 percent non-Hispanic Black, Hispanic, and non-Hispanic White, respectively) with metastatic NSCLC without EGFR, ALK, or ROS1 alterations who underwent first-line immunotherapy were followed for a median of 12.0 months.
The researchers found that overall survival (OS), progression-free survival (PFS), and time to discontinuation (TTD) were similar among racial and ethnic groups. Longer OS was seen for patients with an ECOG PS of <2 versus ≥2 at the start of immunotherapy. Programmed death-ligand 1 expression (<50 versus ≥50 percent) and body mass index (BMI) were associated with PFS; associations were also seen for ECOG PS and BMI with TTD. ECOG PS was the only significant variable in a multivariable analysis of OS and PFS.
"These findings help identify potential factors that can be addressed to optimize outcomes and care while patients are undergoing immunotherapy, and they highlight the need for randomized trials evaluating the efficacy of immunotherapy in high-risk patients such as those with poor ECOG PS," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
FRIDAY, May 17, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), perioperative treatment with nivolumab results in significantly longer event-free...
AACR Delivers Report on Disparities in Cancer Progress
WEDNESDAY, May 15, 2024 -- In its biennial Cancer Disparities Progress Report published today, the American Association for Cancer Research presents the latest statistics on...
Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
MONDAY, April 22, 2024 -- The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.